European Medicines Agency Counts The Cost Of Brexit
Activities To Be Restarted With Fewer Staff
Executive Summary
As the EMA settles into its permanent headquarters in Amsterdam, it hopes that new recruits will swell its depleted staff numbers. But much will depend on the necessary expertise being available, particularly following the loss of access to experts working at the UK regulator, the MHRA.
You may also be interested in...
European Medicines Agency Restructures To Tackle New Challenges
A restructuring involving the setting up of four new task forces is aimed at improving how the European Medicines Agency responds to issues such as permanent staff reductions and challenges in regulatory science, digital business transformation, and clinical trial strategy.
Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package
The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.
EU Bodies Agree On Ways To Future-Proof EMA Funding System
EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.